Dark

Check out our Dark Pool Levels

GNCA
GENOCEA BIOSCIENCES INC
stock OTC

Inactive

Aug 30, 2022

0.0110USD-78.431%(-0.0400)10,042,378

Pre-market

0.00USD-100.000%(-0.06)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 5, 2022

05:47PM EST Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January. GlobeNewswire Inc

Jan 4, 2022

07:22AM EST Genocea Biosciences Enters R&D Collaboration And Option Agreement With Janssen Benzinga

07:19AM EST Genocea Biosciences Enters Into Inhibigen R&D Collaboration And Option Deal With Janssen RTTNews

07:00AM EST Enters into Inhibigen R&D collaboration and option agreement with Janssen GlobeNewswire Inc

Oct 28, 2021

08:26AM EDT The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug Benzinga

07:38AM EDT Genocea Biosciences Q3 EPS $(0.05) Beats $(0.20) Estimate Benzinga

07:00AM EDT GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For October 28, 2021 Benzinga

Oct 24, 2021

11:45AM EDT The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More Benzinga

Sep 28, 2021

04:30PM EDT Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in October. GlobeNewswire Inc

Sep 13, 2021

04:52PM EDT Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Jennifer Herron, Senior Vice President & Chief Commercial Officer at ADC Therapeutics SA ("ADCT"), has joined its board of directors. GlobeNewswire Inc

Sep 7, 2021

07:41PM EDT Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following virtual conferences in September. GlobeNewswire Inc

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Jul 29, 2021

07:00AM EDT GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues GlobeNewswire Inc

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 13, 2021

10:11AM EDT Genocea Biosciences Starts Dosing In Mid-Stage GEN-011 Study In Solid Tumors Benzinga

07:36AM EDT Genocea Doses First Patient In Phase 1/2a TiTAN Clinical Trial For GEN-011 Neoantigen-Targeted T cell Therapy Benzinga

07:30AM EDT Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the dosing of the first patient in its TiTAN study, a Phase 1/2a clinical trial testing its GEN-011 therapy. GEN-011 represents a new category of autologous solid tumor cell therapy: neoantigen-targeted peripheral T cells (NPTs). GlobeNewswire Inc

Jun 4, 2021

09:00AM EDT Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination was 15 months GlobeNewswire Inc

Apr 29, 2021

07:00AM EDT GEN-011 and GEN-009 immuno-oncology programs continue to advance GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 22, 2021

04:30PM EDT Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quarter 2021 financial results and corporate update conference call and live audio webcast on Thursday, April 29 at 8:30 a.m. ET. GlobeNewswire Inc

Apr 12, 2021

10:20AM EDT Genocea Biosciences Saturday Morning Announced Co. To Present Novel Preclinical Inhibigen Data At American Association For Cancer Research Conference Benzinga

Apr 10, 2021

08:30AM EDT Pro-tumor effects detected as early as four days after Inhibigen administration GlobeNewswire Inc

Apr 6, 2021

04:30PM EDT Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13th at 2:15 P.M. ET. GlobeNewswire Inc

07:43AM EDT SVB Leerink Maintains Outperform on Genocea Biosciences, Raises Price Target to $6 Benzinga

Mar 2, 2021

04:01PM EST Genocea to Present at the H.C. Wainwright Global Life Sciences GlobeNewswire Inc

Feb 11, 2021

11:21AM EST Needham Maintains Buy on Genocea Biosciences, Lowers Price Target to $6 Benzinga

07:30AM EST GEN-011 and GEN-009 clinical trials continue to advance GlobeNewswire Inc

03:51AM EST Earnings Scheduled For February 11, 2021 Benzinga

Feb 4, 2021

04:05PM EST Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth quarter 2020 financial results and corporate update conference call and live audio webcast onThursday, February 11that 8:30 a.m. ET. GlobeNewswire Inc

Jan 28, 2021

06:00AM EST Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigensof anti-tumor T cell responses and excluding Inhibigens, or neoantigens of pro-tumor T cell responses GlobeNewswire Inc

Jan 19, 2021

06:54PM EST Genocea to Participate in the B. Riley GlobeNewswire Inc

Jan 4, 2021

04:53PM EST Genocea Biosciences 8-K Shows. Co Presentation For Upcoming Presentation: Sees Longer-Term Efficacy For GEN-009 Neoantigen Vaccine In Combo With Checkpoint Inhibitor In Q2'21 Benzinga

04:19PM EST Genocea to Present at the H.C. Wainwright Virtual BioConnect GlobeNewswire Inc

Nov 12, 2020

08:00AM EST Genocea Biosciences, Inc.(NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18th at 8:40 a.m. ET. GlobeNewswire Inc

Nov 9, 2020

11:32AM EST Genocea Biosciences shares were trading higher after the company announced positive GEN-009 clinical results and provided an update on its GEN-011 program and New InhibigenTM Mechanism of action data. Benzinga

08:07AM EST Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020 Benzinga

08:01AM EST Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additiveclinical benefit in combination with PD-1-based therapies GlobeNewswire Inc

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

06:21PM EST Genocea To Host Investor Call Highlighting New GEN-009 Clinical And Immunogenicity Data To Be Presented At Virtual SITC 2020 Benzinga

Oct 29, 2020

07:52AM EDT Genocea Biosciences Q3 EPS $(0.26) Misses $(0.24) Estimate Benzinga

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

07:00AM EDT Genocea Provides Third Quarter 2020 Corporate Update GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 14, 2020

05:22PM EDT Will showcase clinical and immune responsesfrom the ongoing GEN-009 Phase 1/2a trial GlobeNewswire Inc

Sep 22, 2020

07:37AM EDT Genocea: FDA Accepts GEN-011 IND Application RTTNews

07:30AM EDT Genocea Announces FDA Acceptance of GEN-011 IND Application Benzinga

Sep 17, 2020

03:16AM EDT Genocea Presents Follow-up Data From GEN-009 Neoantigen Vaccine Phase 1/2a Trial RTTNews

03:00AM EDT Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit to PD-1 inhibitor therapy GlobeNewswire Inc

Sep 3, 2020

06:53PM EDT Genocea to Present at the ESMO Virtual Congress and Two Investor GlobeNewswire Inc

Aug 18, 2020

04:22PM EDT Genocea Biosciences Files Stock Shelf Of Up To 21.2M Shares Of Common Stock By Selling Stockholders Benzinga

Jul 30, 2020

02:32PM EDT Mid-Afternoon Market Update: Nasdaq Turns Higher; Kraton Shares Plummet Benzinga

12:37PM EDT Needham Maintains Buy on Genocea Biosciences, Lowers Price Target to $7 Benzinga

12:17PM EDT Mid-Day Market Update: Crude Oil Down 3%; At Home Group Shares Spike Higher Benzinga

10:15AM EDT Mid-Morning Market Update: Markets Open Lower; Procter & Gamble Tops Q4 Views Benzinga

09:56AM EDT Genocea Biosciences Earlier Reported Will Present Prelim. Data For Neoantigen Vaccine GEN-009 In Combo With Checkpoint Inhibitors: '3 of 5 patients achieved separate RECIST responses after GEN-009 administration' Benzinga

07:00AM EDT Genocea to Present Positive Preliminary Clinical Data Evaluating GlobeNewswire Inc

Jul 27, 2020

07:57AM EDT Benzinga Pro's Top 5 Stocks To Watch For Mon., Jul. 27, 2020: FB, BA, ALEC, SCKT, GNCA Benzinga

Jul 23, 2020

10:01AM EDT HC Wainwright & Co. Maintains Buy on Genocea Biosciences, Lowers Price Target to $9 Benzinga

07:08AM EDT Genocea Q2 Net Loss $11.3M vs $6.5M In Same Period Last Year, Cash, Cash Equivalents At Qtr. End $22.1M vs $40.1M As Of Dec. 31, 2019 Benzinga

07:07AM EDT Genocea Biosciences Reports Filed Investigational New Drug Application For GEN-011, GEN-009 Data Update Planned For Jul. 30 At 8 a.m. EDT, Private Placement With Leading Life Science Investment Funds Benzinga

07:00AM EDT Upcoming GEN-009 data update planned for July 30th at 8 a.m. EDTFiled IND application for GEN-011 and is working with the FDA to provide additional informationPrivate Placement with Leading Life Science Investment Funds GlobeNewswire Inc

04:30AM EDT Earnings Scheduled For July 23, 2020 Benzinga

Jul 22, 2020

12:02PM EDT Mid-Day Market Update: Crude Oil Down Over 1%; Blink Charging Shares Surge Benzinga

09:06AM EDT Genocea Biosciences Reports Private Placement Financing Of Up To $80M Benzinga

09:03AM EDT Genocea Announces Private Placement Financing of Up to $80 Million GlobeNewswire Inc

Jul 20, 2020

08:09AM EDT Genocea Biosciences to Share data on its GEN-009 Trial on July 30th, Company Submitted an Investigational New Drug Application in June for GEN-011 Benzinga

08:00AM EDT Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced updates to its clinical programs, the neoantigen vaccine GEN-009 and the neoantigen cell therapy, GEN-011. GlobeNewswire Inc

Jul 16, 2020

08:00AM EDT Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its second quarter 2020 financial results and corporate update conference call and live audio webcast onThursday, July 23rdat 8:30 a.m. EDT. GlobeNewswire Inc

Share